Total Payments
$56,782
2024 Payments
$3,980
Companies
65
Transactions
699
Medicare Patients
3,170
Medicare Billing
$288,992
Payment Breakdown by Category
Other$28,670 (50.5%)
Consulting$15,538 (27.4%)
Food & Beverage$10,895 (19.2%)
Travel$1,180 (2.1%)
Education$498.83 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,171 | 24 | 47.9% |
| Consulting Fee | $15,538 | 7 | 27.4% |
| Food and Beverage | $10,895 | 643 | 19.2% |
| Honoraria | $1,500 | 1 | 2.6% |
| Travel and Lodging | $1,180 | 7 | 2.1% |
| Education | $498.83 | 17 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32,325 | 65 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,539 | 37 | $0 (2023) |
| Lilly USA, LLC | $3,064 | 14 | $0 (2022) |
| PFIZER INC. | $2,372 | 78 | $0 (2024) |
| TG Therapeutics, Inc. | $2,330 | 2 | $0 (2022) |
| GlaxoSmithKline, LLC. | $1,950 | 1 | $0 (2020) |
| Amgen Inc. | $1,262 | 47 | $0 (2023) |
| Puma Biotechnology, Inc. | $1,216 | 7 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,177 | 77 | $0 (2021) |
| MorphoSys, US Inc. | $1,140 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,980 | 15 | Merck Sharp & Dohme LLC ($3,360) |
| 2023 | $3,570 | 8 | Merck Sharp & Dohme LLC ($3,341) |
| 2022 | $10,862 | 11 | Merck Sharp & Dohme LLC ($5,616) |
| 2021 | $12,852 | 13 | Merck Sharp & Dohme Corporation ($8,670) |
| 2020 | $11,563 | 41 | Merck Sharp & Dohme Corporation ($7,568) |
| 2019 | $7,659 | 203 | Merck Sharp & Dohme Corporation ($3,609) |
| 2018 | $3,040 | 204 | Novartis Pharmaceuticals Corporation ($479.43) |
| 2017 | $3,256 | 204 | Amgen Inc. ($787.10) |
All Payment Transactions
699 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $6.08 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $84.18 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $6.42 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | PFIZER INC. | TALZENNA (Drug), XTANDI | Education | In-kind items and services | $3.78 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $6.22 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $61.24 | General |
| 06/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $117.95 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $90.37 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $144.44 | General |
| Category: Oncology | ||||||
| 02/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $6.49 | General |
| Category: ONCOLOGY | ||||||
| 12/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $109.65 | General |
| Category: Oncology | ||||||
| 07/12/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: ONCOLOGY | ||||||
| 06/16/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $83.85 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $7.72 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $119.06 | General |
| Category: Oncology | ||||||
| 04/03/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 12/22/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,275.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 736 | 942 | $131,354 | $64,244 |
| 2022 | 9 | 831 | 1,070 | $147,494 | $77,891 |
| 2021 | 9 | 819 | 1,080 | $144,993 | $79,729 |
| 2020 | 10 | 784 | 1,043 | $136,628 | $67,129 |
Total Patients
3,170
Total Services
4,135
Medicare Billing
$288,992
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 96 | 125 | $18,720 | $8,608 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 57 | 57 | $14,592 | $7,725 | 52.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 110 | 155 | $13,823 | $7,274 | 52.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 108 | 158 | $13,948 | $7,114 | 51.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 60 | 98 | $14,108 | $6,806 | 48.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 50 | $15,350 | $6,440 | 42.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 65 | 94 | $10,246 | $5,631 | 55.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 48 | $9,984 | $4,754 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 39 | 39 | $7,683 | $3,799 | 49.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $5,122 | $2,430 | 47.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $3,328 | $1,658 | 49.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 39 | 39 | $2,184 | $986.48 | 45.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 15 | 16 | $906.00 | $427.68 | 47.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 12 | 13 | $728.00 | $320.76 | 44.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 11 | $632.00 | $269.90 | 42.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 120 | 196 | $24,572 | $14,217 | 57.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 100 | 150 | $18,767 | $10,792 | 57.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 62 | 69 | $21,183 | $10,364 | 48.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 118 | 163 | $13,856 | $7,346 | 53.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 91 | 122 | $13,298 | $6,414 | 48.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 46 | 46 | $11,776 | $6,174 | 52.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 122 | $10,285 | $5,545 | 53.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $8,668 | $4,296 | 49.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 37 | 37 | $7,289 | $3,432 | 47.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 25 | $4,680 | $2,757 | 58.9% |
About Dr. Pablo Bedano, MD
Dr. Pablo Bedano, MD is a Hematology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1063551240.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pablo Bedano, MD has received a total of $56,782 in payments from pharmaceutical and medical device companies, with $3,980 received in 2024. These payments were reported across 699 transactions from 65 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($27,171).
As a Medicare-enrolled provider, Bedano has provided services to 3,170 Medicare beneficiaries, totaling 4,135 services with total Medicare billing of $288,992. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Indianapolis, IN
- Active Since 02/05/2007
- Last Updated 09/06/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1063551240
Products in Payments
- KEYTRUDA (Biological) $28,578
- IMFINZI (Biological) $2,775
- UKONIQ (Drug) $2,330
- DAURISMO (Drug) $1,500
- Nerlynx (Drug) $1,216
- MONJUVI (Drug) $1,140
- IMLYGIC (Biological) $775.50
- OPDIVO (Biological) $654.47
- TAGRISSO (Drug) $462.69
- Abraxane (Drug) $338.69
- clonoSEQ (Device) $338.46
- GILOTRIF (Drug) $269.20
- AFINITOR (Drug) $256.28
- TECENTRIQ (Biological) $227.37
- JADENU (Drug) $213.80
- Imbruvica (Drug) $210.35
- JAKAFI (Drug) $199.88
- IBRANCE (Drug) $176.52
- Alecensa (Biological) $167.17
- MEKINIST (Drug) $165.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Indianapolis
Dr. Luke Akard, M.d, M.D
Hematology — Payments: $510,050
Hematology $510,050
Attaya Suvannasankha, M.d, M.D
Hematology — Payments: $224,074
Hematology $224,074
Bert O'neil, Md, MD
Hematology — Payments: $160,161
Hematology $160,161
Felix Mensah, Md, MD
Hematology — Payments: $114,460
Hematology $114,460
Gregory Smith, Md, MD
Hematology — Payments: $75,453
Hematology $75,453
Sumeet Bhatia, Md, MD
Hematology — Payments: $24,304
Hematology $24,304